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Abstract
Background: The efficacy of screening for colorectal cancer using a simple blood-based assay for
the detection of tumor cells disseminated in the circulation at an early stage of the disease is gaining
positive feedback from several lines of research. This method seems able to reduce colorectal
cancer mortality and may replace colonoscopy as the most effective means of detecting colonic
lesions.
Methods: In this work, we present a new microarray-based high-throughput screening method to
identifying candidate marker mRNAs for the early detection of epithelial cells diluted in peripheral
blood cells. This method includes 1. direct comparison of different samples of colonic mucosa and
of blood cells to identify consistent epithelial-specific mRNAs from among 20,000 cDNA assayed
by microarray slides; 2. identification of candidate marker mRNAs by data analysis, which allowed
selection of only 10 putative differentially expressed genes; 3. Selection of some of the most
suitable mRNAs (TMEM69, RANBP3 and PRSS22) that were assayed in blood samples from normal
subjects and patients with colon cancer as possible markers for the presence of epithelial cells in
the blood, using reverse transcription – polymerase chain reaction (RT-PCR).
Results: Our present results seem to provide an indication, for the first time obtained by genome-
scale screening, that a suitable and consistent colon epithelium mRNA marker may be difficult to
identify.
Conclusion: The design of new approaches to identify such markers is warranted.
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Background
Early detection seems to be a key factor in reducing rates
of death from colorectal cancer [1], one of the commonest
cancers in the world [2]. Current methods of screening
include fecal occult blood testing (FOBT), flexible sig-
moidoscopy, barium enema, and colonoscopy. Recently,
"virtual" (computed tomographic) colonography has
been proposed as a relatively non-invasive alternative to
colonoscopy for detecting colorectal neoplasia [3]. In
addition, novel methods of detecting common molecular
alterations in colorectal cancer cells, such as methylation
changes in fecal DNA [4], are being evaluated. However,
none of these methods is currently widely used for screen-
ing the general population, due either to patient discom-
fort or low sensitivity/specificity.
The search for epithelial cells as a screening tool in the
patient's blood represents an important field of research
for early detection of epithelial cancers. The rationale for
using this as a colorectal cancer screening method lies in
the fact that solid tumors as small as 2 mm diameter typ-
ically display active angiogenesis [5] and hence are capa-
ble of releasing tumor cells into the peripheral blood; in
the earlier stages of the disease, disseminated cells are not
capable of forming metastases, but they may provide a
clue for cancer detection [6].
The concept of circulating tumor cell (CTC) detection has
so far been put forward for breast cancer in particular. Sev-
eral authors in this field have established that: CTCs are
rare events occurring at a frequency of approximately one
tumor cell per 1× 105–7 peripheral blood mononuclear
cells [7]; methods to identify CTCs must distinguish
between epithelial and hematopoietic cells in blood while
it may not be essential to distinguish between cancer and
normal epithelial cells [8]; selection based upon physical
properties such as morphology, size, and weight have lim-
itations in both sensitivity and specificity [8]. A new sys-
tem proposed for breast cancer is based on counting
epithelial cells, which are separated from the blood by
antibody-coated magnetic beads and identified using flu-
orescent labeled antibodies against cytokeratin, as well as
a fluorescent nuclear stain and fluorescent cytokeratin
antibodies [9].
Detection of cancer cells in the blood could employ an
epithelial-specific mRNA, which might be revealed in the
patient's blood sample via amplification by RT-PCR
(reverse transcription-polymerase chain reaction). This
approach has been applied starting both from unfrac-
tioned whole blood [10-13] and from blood fractions, e.g.
separated mononuclear cells or immunomagnetically
enriched cancer cells [14-22].
While using RT-PCR could overcome the problems of lack
of sensitivity associated with other methods of identifica-
tion, the selection of epithelial-specific mRNA is difficult.
Previous studies on this topic have mostly been per-
formed in relation to breast cancer, and only a few studies
have included colorectal cancer [12,15,20-28]. A recent
review [29] has led to the conclusion that methods of
identifying epithelial specific mRNA markers are not reli-
able at this point, and need additional study.
In a previous work describing a bioinformatic method
aimed at identifying putative epithelial-specific mRNAs
suitable for detection of colorectal CTC in the blood, we
showed that for all the 15 genes investigated it failed to
distinguish between normal and patients' blood by quali-
tative RT-PCR [30].
In this work, we present a new microarray-based high-
throughput screening approach to identifying candidate
marker mRNAs for early detection of epithelial cells
diluted in peripheral blood cells. This method included:
direct comparison of different samples of colon mucosa
and blood cells, searching for epithelial-specific genes
among the 20,000 genes assayed by microarray slides;
identification of candidate marker mRNAs by data analy-
sis, which allowed for only 10 putative differentially
expressed genes; selection of some of the most suitable
mRNAs (TMEM69,  RANBP3  and  PRSS22) that were
assayed in blood samples from normal subjects and
patients with colon cancer as possible markers for the
presence of epithelial cells in the blood, using RT-PCR.
None of the 3 candidate mRNAs was proven to be absent
from the blood of normal subjects. This first study based
on a systematic search for epithelial-specific mRNAs in the
blood reveals how difficult it is to identify robust indica-
tors of tissue-specific expression.
Methods
RNA sources
A peripheral blood sample (10–15 mL) was obtained
from 2 patients on the brink of surgery and from 4 healthy
donors (Table 1). The study was conducted in compliance
with the Helsinki Declaration, it was approved by the sen-
ior staff committee, a board regulating non-interventional
study comparable to an institutional review board; all
patients and subjects involved gave their written informed
consent. To reduce contamination of samples with skin
epithelial cells from the needle stick, the first mL of blood
was discarded. Then 10–15 mL of whole blood, drawn
into an EDTA tube, was treated for RNA extraction within
one hour of being drawn, as described below. We also
used total RNA samples from: a) normal human periph-
eral leukocytes pooled from 250 male/female Caucasians,
aged 18–40 (BD-Biosciences, Clontech, Palo Alto, CA); b)
normal human colon with mucosal lining pooled from aBMC Cancer 2006, 6:250 http://www.biomedcentral.com/1471-2407/6/250
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suddenly deceased 35 year old Caucasian female (BD-Bio-
sciences); c) colon adenocarcinoma isolated from a 28
year old Caucasian male) (BD-Biosciences); d) normal
human colon and adenocarcinoma isolated from an 82
year-old male (mucosa margin respectively disease free
and adenocarcinoma-bearing, Stratagene, La Jolla, CA); e)
normal human colon pooled from three males aged 50,
76 and 94 (Stratagene, La Jolla, CA).
Automated RNA extraction
Total cellular RNA was extracted from peripheral blood
samples using the ABI PRISM 6100 system. This new 96-
well platform instrument is engineered for run-to-run and
well-to-well high-yield purification that is reproducible
and free of cross-contamination. Cellular lysates or
homogenized tissue lysates are added to the tray and vac-
uum is applied under user interface control for a specific
time and at an electronically controled pressure.
Blood samples were lysed within one hour of being
drawn, diluting 1 mL of whole blood with 1 mL of phos-
phate buffered saline (PBS) and adding 2 mL of lysis solu-
tion provided by the manufacturer. The lysate was stored
at -20°C up to RNA extraction by ABI PRISM 6100. Extrac-
tion was performed according the manufacturers' instruc-
tions. Total RNA extracted from 1 mL of peripheral blood
was subjected to standard ethanol precipitation, and the
pellet was re-suspended in 20 μL of steril bidistillated
water and stored at -20°C.
DNA microarray screening and analysis
Comparison of blood and colon global gene expression
was performed using hybridization of the microarray
MWG Pan Human 40K array A, an oligonucleotide-based
array on a glass slide containing 20,000 gene-specific
probes (50 mer) (MWG Biotech AG, Ebersberg, Ger-
many).
Gene expression analysis was performed by a process of
RNA extraction, reverse transcription and labeling of
cDNA. Reference (i.e. blood-derived) and investigated
(i.e. colon mucosa-derived) cDNA are in this process
labeled with different dyes and then co-hybridized on
slides containing cDNA fragments. The slides are then
scanned with a laser system, and two false color images
are generated for each hybridization with cDNA from the
investigated and reference sample. The overall result is the
generation of a so-called genetic portrait.
RNA was purchased or extracted as described above. Ten
micrograms of total RNA were used for each sample.
cDNA was synthesized using a CyScribe Post-Labeling Kit
Cat. no RPN5660 (Amersham Biosciences, Europe,
Freiburg, Germany) that provides reagents for preparation
of Cy3 and Cy5 labeled cDNA probes. The first step
involves the incorporation of aminoallyl-dUTP (AA -
dUTP) during cDNA synthesis using an optimized nucle-
otide mix, RNA hydrolysis and purification of amino
allyl-modified cDNA, while a second step involves chem-
ically labeling the amino allyl-modified cDNA using the
CyDye NHS-esters provided and purifying CyDye-
labelled cDNA with autoseq G-50 columns (CyScribe GFX
Purification kit Cat no.27-9606-02, Amersham Bio-
sciences, Europe, Freiburg, Germany).
We added respectively 130 μL of preheated hybridization
buffer to Cy3- or Cy5-fluorescently labeled reference, and
proceeded to investigate cDNA. For hybridization we used
the microarray "Gene Frame" as a cover slip to prevent
reagent loss due to evaporation during incubation at
37°C overnight.
In our three independent hybridization experiments: i)
normal human peripheral leukocytes pooled from 250
male/female Caucasians cDNA were labeled with Cy5 and
normal human colon with mucosal lining pooled from a
35-year old Caucasian female cDNA was labeled with
Cy3; ii) locally extracted human peripheral blood RNA
pooled from 4 normal Caucasians (Table 1, subjects no. 3,
4, 5 and 6) cDNA was labeled with Cy5 and colon adeno-
carcinoma isolated from a 28-year old male Caucasian
cDNA was labeled with Cy3; iii) locally extracted human
peripheral blood pooled from 2 patients with colon can-
cer cDNA was labeled with Cy3 and cDNA from adenocar-
cinoma disease isolated from an 82-year old male was
labeled with Cy5. We later refer to these experiments as
slide nos. 1, 2 and 3, respectively.
Washing was performed three times for 10 min with 1×
saline sodium citrate (SSC), 0.1% sodium dodecyl sulfate
(SDS) at 42°C, and three times for 5 min with 0.1× SSC at
room temperature. Slides were dried by centrifugation for
2 min at 2000 rpm.
Table 1: Colon cancer patients and control subject
Patient no. Age Sex Stagea Therapy
1 62 F T3N1M0 S.R.
2 73 F T4NXM1 B.P.
Controls
38 3 M
48 3 M
58 4 F
67 9 M
aStaging according to American Joint Committee on Cancer (AJCC) 
and International Union Against Cancer. M, male; F, female. B.P., by-
pass; S.R., sigmoid resection.BMC Cancer 2006, 6:250 http://www.biomedcentral.com/1471-2407/6/250
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Array image and data analysis
A GenePix 4000a DNA microarray scanner (Axon, Union
City, CA, USA) was used to scan the slides under dried
conditions. The laser power for scanning green and red
colors was adjusted in order to obtain a global intensity
ratio near to 1. If necessary, further washes were per-
formed to reduce the aspecific background.
Each spot was defined using the grid schema provided by
the manufacturer, with manual adjustment for the posi-
tioning of spot blocks. Spots showing no signal or obvi-
ous defects were accordingly flagged by visual inspection
and excluded from analysis.
Data were extracted with GenePix Pro3.0 software (Axon
Instruments). The median of the pixel intensities for each
spot and for the corresponding surrounding area (back-
ground) was obtained for each channel.
We imported data into the FileMaker Pro 8 database (File-
Maker Inc., Santa Clara, CA) so as to search for genes con-
sistently over-expressed in colon versus blood tissue in all
three experiments performed.
Reverse transcription-polymerase chain reaction (RT-
PCR) amplification
Total RNA (about 2.25 μg) from peripheral blood or from
human colon was reverse transcribed in a final volume of
50 μL in the presence of: 500 mM each of deoxynucleotide
triphosphate (dNTP), 200 U reverse transcriptase (Murine
Moloney Leukemia Virus) with companion buffer 1 ×
(Promega, Madison, WI, U.S.A.), oligo dT-15 5 μM. The
incubation was performed at 42°C for 1 h, followed by
denaturation at 95°C for 5 min.
The primers for amplification were designed using the
software Amplify [31], following standard criteria. Primer
sequences and predicted product size are given in Table 2.
PCR experiments were performed in 25 μL final volume,
containing 3 μL RT mix, 1U Taq Polymerase (TaKaRa,
Shiga, Japan) with companion reagents (0.2 mM each
dNTP, 1.5 mM MgCl2, 1× PCR buffer), and 0.3 μM of each
primer. An initial denaturation step of 2 min at 94°C was
followed by amplification for 30–45 cycles (30 sec at
94°C, 30 sec at 64°C, 30 sec at 72°C) and final extension
for 7 min at 72°C. All the RT-PCR products obtained were
gel analysed following standard methods [32]: ethidium
bromide incorporation in the gel (0.5 μg/mL final con-
centration), transillumination at 300 nm, and photogra-
phy.
Results
Automated RNA extraction
The automated RNA extraction applied method allowed
for quick extraction of a reproducible amount of total
RNA from all the samples analysed, confirming our previ-
ous results [30]. The amount of total RNA obtained from
1 mL of each peripheral blood sample was about 5 μg, at
a concentration of 20 ng/mL. Since the number of circu-
lating tumor cells might be very low, if compared to blood
cells, we performed a precipitation step to obtain a final
RNA concentration of 0.25 μg/μL. Quality control on aga-
rose minigel confirmed the integrity of total RNA.
Array image and data analysis
The dataset used as the base for analysis was the "results"
file provided by the software GenePix 3. The "background
median" was the median of the pixel intensities in the
area surrounding the spot, while the "feature median" was
the median of the pixel intensities in the area inside the
spot. The spot intensity was then calculated by subtracting
the background median value from the feature median
value. The original datasets for experiments 1, 2 and 3 as
defined above are provided as supplementary data [33].
After data importation into a relational database manage-
ment system (FileMaker Pro 7 for Macintosh), we checked
Table 2: Primers used for RT-PCR
Primer Sequence (5' → 3') Direction Nt 5'a Expected size (bp)
PRSS22 ctatcatcgactcggaagtc f 668 676
gatatgtgggcagggttaca r 1343
RANBP3 gctcgtacgagtgtagacactgggc f 2195 191
agggacctcgacagagctgtgcct r 2385
TMEM69 gatgtctctccagcaaaacttttc f 281 299
ctggctccataagccatctgag r 579
B2M gcgggcattcctgaagctgac f 25 586
tacatcaaacatggagacagcac r 610
a Nt 5' indicates the position of the nucleotide (Nt) at the 5' end of the primer. [GenBank:AB021288 (B2M), AB010779 (PRSS22), NM_003624 
(RANBP3), NM_016486 (TMEM69)]. B2M, β-2 microglobulin; f, forward; r, reverse; bp, base pair.BMC Cancer 2006, 6:250 http://www.biomedcentral.com/1471-2407/6/250
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and normalized the data. We used the "total intensity"
normalization factor [34] to balance the green/red series
of measurements for each slide.
For the analysis, we considered only those genes (out of
20,160 total probes) meeting the following criteria in all
three experiments performed: presence of colon-related
"intensity" values greater than 0; absence of any related
spot visually localized in areas with artifacts, manually
flagged by the operator as "bad" (code -100); absence of
any related spot flagged as "not found" (code -50) by the
GenePix software, by internal criteria including number of
pixels above background threshold or feature diameter –
usually this means that the expression level cannot be
affordably assessed for technical (artifactual area) reasons.
To identify colon-expressed genes that were significantly
under-expressed in blood cells, we searched the normal-
ized dataset for all genes whose expression ratio colon/
blood was above the best threshold able to identify a cri-
terion-matching gene.
In order to have meaningful numbers when dividing
"colon-related" values by "blood-related" values, we
made a transformation so that all "blood-related" values
equal to or lower than "0" were taken as equal to "1". This
enabled values at the lowest range of detection, e.g. "2" in
the colon and "1" in the blood, to be measured as at least
2-fold increases. Only a colon value of 1 on a blood value
of 0 ratio could go undetected, being transformed into 1/
1, but such a ratio would have no significance for our pur-
poses. The normalized and transformed values for the
11,529 genes meeting the criteria above described are tab-
ulated in a file available on line [33].
Searching for the greatest colon/blood ratios in all the
experiments, we were able to identify 10 genes matching
the above described criteria, which proved to have a ratio
of at least 2.8: [GenBank : AF19551 (PURG), NM_016486
(TMEM69), NM_003624 ( RANBP3), AB010779
(PRSS22), AF080227 ( EED), BC009048 ( TINAGL1),
BC021574 ( G6PC3), BC023542 ( SORT1), BC028610
(LRRC34) and M63967 (ALDH1B1)].
Useful candidates might have been lost by our analysis
when the whole series of three measurements was not
available due to slide artifacts. To test this hypothesis, we
finally searched for colon mRNAs over-expressed in at
least two slides, when the third measurement proved to
have been labeled as "bad" by the software (104 and
7,469 spots out of 20,160 in slide nos. 2 and 3, respec-
tively) or by visual inspection (43, 1,533 and 338 spots
out of 20,160 in slides 1, 2 and 3, respectively). In this
way, only a few additional potential candidates were iden-
tified: 4 considering slides no. 2 and 3, 6 for slides no. 1
and 3, and none for slides no. 2 and 3. However, in these
cases one or more of the following conditions recurred:
values were in the low range of detection for both chan-
nels, blood channel values were positive, or colon chan-
nel values were "0", thus implying that the low number of
mRNA candidates found by analyzing only the values
detectable in all three experiments was not due to techni-
cal artifacts.
Reverse transcription-polymerase chain reaction (RT-
PCR) amplification
Although we did not find any mRNA with an ideal expres-
sion level difference between colon and blood tissues, we
chose three genes out of the 10 identified as above to for-
mally exclude their suitability as epithelial markers in the
blood. We chose the two genes with the greatest mean
colon/blood ratio throughout the three experiments
(RANBP3 and PRSS22), and we also selected the gene with
the greatest absolute expression value in the colon
(TMEM69). A data summary for these genes is summa-
rized in Table 3.
RT-PCR products of the expected size were all obtained
from at least some RNA control subject samples for these
three genes.
Gene expression was tested for each gene on total RNA
derived from: 4 normal peripheral blood samples (sub-
jects no. 3, 4, 5 and 6 in Table 1, respectively), 1 commer-
cial pool of RNA leukocytes from 250 normal subjects, 1
pool of two colon cancer patients' peripheral blood sam-
ples (subjects no. 1 and 2 in Table 1, respectively). Nor-
mal and neoplastic colon mucosa were used as controls
for gene expression.
[GenBank : AB010779 (PRSS22)] mRNA was detected in
2 out of 5 normal peripheral blood samples (Fig. 1A, lanes
1–5); aspecific amplification was also observed. [Gen-
Bank : NM_003624 (RANBP3)] mRNA was detected in 4
out of 5 normal peripheral blood samples (Fig. 1B, lanes
1–5). [GenBank : NM_016486 (TMEM69)] mRNA was
detected in 4 out of 4 tested normal peripheral blood sam-
ples (Fig. 1C, lanes 1–4). All genes investigated were
expressed in both normal and neoplastic colon mucosa.
Discussion and conclusion
If tumor cell shedding is an early event in tumorigenesis,
it may be possible to detect cancer cells in the blood-
stream before the primary tumor is large enough to be
detected by standard screening examinations [35].
Although detection of circulating tumor cells (CTCs) in
peripheral blood has been of interest for over a century
[36], only in recent times has the development of meth-
ods to detect them received attention.BMC Cancer 2006, 6:250 http://www.biomedcentral.com/1471-2407/6/250
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The aim of this work was to use gene expression profiling
of normal or cancer colon mucosa in comparison with
normal or colon cancer patients' peripheral blood, in
order to identify a set of genes that could be used for
detection of CTCs in the peripheral blood from patients
with colorectal cancer, using a standardized PCR test
according to the World Health Organization criteria for a
screening test: acceptability, practicability, high specificity
and high sensitivity [37].
DNA microarray technology allows one to investigate
gene expression in parallel for a very large number of
genes, and it has the ability to detect a change of expres-
sion between two compared cellular samples. In particu-
lar, we chose an MWG Pan Human 40K array A (MWG
Biotech AG Ebersberg, Germany), a recent type of oligo-
nucleotide array on glass slides containing 20,000 gene-
specific oligonucleotide probes. These are particularly
suitable for marker selection owing to the big number of
known genes spotted on. In three independent hybridiza-
tion experiments we compared RNA samples deriving
from colon cells with RNA samples deriving from periph-
eral blood cells.
Various popular current approaches try to identify mark-
ers of cancer progression by comparing normal and neo-
plastic colon mucosa. Comparison of global gene
expression profiles of purified CTC and CTC-depleted
blood from patients with colon cancer has also recently
been reported [21], no single mRNA proving to be suita-
ble for identification of CTCs. Our approach exploits a
more "biological" concept, focusing on the identification
of consistent "epithelial" mRNA markers, which ought
not to be present in normal blood.
To this end, we used various different types of compari-
sons regarding the cancerous/normal state, provided that
in each experiment a colon cell sample was compared
with a blood cell sample. In addition, we used both single
and pooled samples, to favor the detection of consistently
up-regulated genes [38,39].
Our analysis failed to identify any single gene that is con-
sistently and strongly over-expressed in colon cells as
compared to blood cells. This finding is in agreement with
recent data on global gene expression, which point out
that a small number of genes may be responsible for even
great differences observed in differentiated cells from dif-
ferent tissues. However, we were able to identify the best
10 genes, among 20,000 tested, which gave the best
attainable colon/blood expression ratio (at least 2.8:1) in
all three experiments. By a simple qualitative RT-PCR
assay we tested three of these genes (TMEM69, RANBP3
and  PRSS22, suitable for mRNA-specific amplification,
being composed of more than one exon) on RNA samples
from pooled and individual peripheral blood from con-
trol subjects. Interestingly, it has been previously demon-
strated that prosemin, the product encoded by PRSS22
gene, is expressed and secreted by various kinds of cancer
cells, such as glioma, pancreas, prostate, and ovarian cell
lines, and the potential usefulness of this serine protease
as a candidate tumor marker has been put forward [40].
We confirm the utility of a semi-automated method of
RNA extraction (nucleic acid preparation by the ABI
PRISM 6100 system, followed by a precipitation step)
which allowed us to obtain a standard amount of total
RNA from 1 mL of each peripheral blood sample, suitable
for RT-PCR [30]. This method is readily amenable to the
analysis of 48 samples/run, it employs no toxic reagents
and is very fast (30–60 minutes from sample to concen-
trated, intact total RNA). The positivity of the investigated
RNA markers in a small set of blood control samples did
not allow us to consider these candidate genes epithelial-
specific, excluding them from any role in the identifica-
tion of cancer cells in patient blood. This finding is not
unexpected, due to the absence of genes with an ideal
expression level difference, as well as to the need for using
as best potential markers genes with a difference of only
~3-fold in a highly sensitive test such as RT-PCR.
In order to compare our finding with previous results con-
cerning "epithelial" mRNA markers, we searched for
Table 3: Gene data summary.
Gene symbol Gene description Function Summary*
PRSS22 Protease, serine, 22 (Location: 
16p13.3)
Serine-type endopeptidase 
activity
Member of the trypsin family of serine proteases. Enzyme expressed in the airways in a 
developmentally regulated manner. Serine proteases are involved in blood coagulation, 
growth factor processing, the digestion of nutrients, and cell migration. Northern 
hybridization showed that prosemin is expressed predominantly in the pancreas and 
weakly in the prostate and cerebellum.
RANBP3 RAN binding protein 3 
(Location: 19p13.3)
Ran GTPase binding The RAN GTPase plays an essential role in the transport of macromolecules between 
the cytoplasm and the nucleus, cell cycle progression, spindle assembly, nuclear 
organization and nuclear envelope (NE) assembly. RANBP3 (RAN binding protein 3) 
contains FXFG motifs characteristic of a subgroup of nucleoporins, and a C-terminal 
domain showing similarity to RANBP1.
TMEM69 Transmembrane protein 69 
(Location: 17q21.2)
Unknown -
*http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=geneBMC Cancer 2006, 6:250 http://www.biomedcentral.com/1471-2407/6/250
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cytokeratin 20 (KRT20) mRNA spot in our array platform,
Ethidium-bromide stained 1% agarose gel of RT-PCR amplification products Figure 1
Ethidium-bromide stained 1% agarose gel of RT-PCR amplification products. A), PRSS22, B) RANBP3 and C) 
TMEM69 gene expression. Lanes for each gene are labeled with the scheme: 1–4, blood RNA of normal individuals (Table 1, 
subjects no. 3–6, respectively): lane 5, normal leukocytes RNA pooled from 250 subjects (source: BD); lane 6, pooled blood of 
colon cancer patients (Table 1, patients no. 1–2); lane 7 normal human colon with mucosal lining pooled from a control subject 
(source: BD); lane 8 colon adenocarcinoma isolated from a colon cancer patient (source: BD); lane 9, pool of normal mucosa 
from 3 control subjects (source: Stratagene); lanes 10–11, disease-free margin mucosa and colon cancer samples, respectively, 
from the same patient (source: Stratagene). Technical controls: lanes 12–13, PCR positive control (B2M RT-PCR amplification 
products from the same samples tested in lanes 5 and 9, respectively), lane 14–15 PCR negative (water) control; lanes 16–17, 1 
μL molecular size markers MBI V and GeneRuler (Genenco), respectively.
 
A) 
 676 bp 
 
586 bp 
                  1   2   3   4   5   6   7   8   9  10 11 12 13 14 15 16 17        
B) 
586 bp 
191 bp   
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because it has been considered an epithelial marker suita-
ble for the identification of epithelial cells in the blood
[41].
The KRT20 values were in the low range of detection in
our series (from 0 to 12, while the range of normalized
intensity values for colon tissues was 0–31,330, 0–3,329
and 0–4,040 for experiments no. 1, 2 and 3, respectively),
and this gene appeared to be slightly more expressed, in
our samples, in the blood. Actually, in the last few years a
very high number of genes claimed as "tissue specific" by
classical analysis have proved to be expressed in many cell
types if one uses RT-PCR techniques (capable of detecting
a low level of expression) or cDNA microarray method
(capable of scanning many tissues on a large-scale). In
addition, KRT20 mRNA expression in colorectal cancers
has been described as highly variable between 32 different
tumours, with 3/32 cancers not expressing KRT20 mRNA,
and KRT20 mRNA levels varying over three orders of mag-
nitude [42,43]. This provides one explanation for the het-
erogeneity of KRT20 mRNA detection and quantification
by various different authors, and for our failure to detect
any significant amount of KRT20 mRNA in our samples
by the cDNA microarray method.
Alternative approaches to get round the need for a clear
cut-off between positive and negative samples could be
quantitative RT-PCR or the use of a combination of sev-
eral markers so as to attain statistical significance. How-
ever, it is often questioned whether a truly quantitative
RT-PCR method can be consistent among many laborato-
ries, as it is commonly difficult to optimize and interpret
[41,44,45]. Various different RT-PCR based methods have
been widely used in the detection of specific tumour cell
markers, with varying degrees of sensitivity and specificity.
It has been demonstrated that, to avoid non-specific
amplification and thus false positive results, the most
important factor is the particular tumour marker selected,
quite apart from the particular type of RT-PCR variant
adopted [19]. Assays incorporating a combination of mul-
tiple markers seems a reasonable approach, although we
think that the existence of a major locus functioning as a
master marker could be a crucial feature for the applicabil-
ity of the test [30]. From this point of view, our current
results seem to have provided an indication, for the first
time obtained through genome-scale screening, that a
suitable and consistent mRNA marker for detection of epi-
thelial cells in the blood may actually not be present in the
cytoplasm of colon-type cells, suggesting that new
approaches to this problem need to be devised in the
future. However, considering that our analysis investi-
gated 20,000 out of about 25,000 protein-coding human
genes, and that many genes could be expressed in tissue-
specific splicing isoforms for which microarray platforms
are not yet available, there is also the possibility that new
microarray platforms with adjunctive probes for mRNAs
or for specific isoform-splicing mRNAs, as well as plat-
forms with probes for microRNAs [46], will reveal an RNA
marker suitable for reliably detecting epithelial cells in the
human blood.
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